Redefining Heart Failure in Breast Cancer.
作者信息
Volgman Annabelle Santos, Brezden-Masley Christine, Okwuosa Tochi
机构信息
Division of Cardiology, Rush University Medical Center, Chicago, Illinois, USA.
Cancer Program at Sinai Health System and Marvelle Koffler Breast Centre, Toronto, Ontario, Canada.
出版信息
JACC CardioOncol. 2022 Mar 15;4(1):66-68. doi: 10.1016/j.jaccao.2022.02.001. eCollection 2022 Mar.
Abstract
摘要
相似文献
1
Redefining Heart Failure in Breast Cancer.重新定义乳腺癌中的心力衰竭
JACC CardioOncol. 2022 Mar 15;4(1):66-68. doi: 10.1016/j.jaccao.2022.02.001. eCollection 2022 Mar.
2
SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.钠-葡萄糖协同转运蛋白 2 抑制剂在心力衰竭患者中的应用：五项随机对照试验的综合荟萃分析。
Lancet. 2022 Sep 3;400(10354):757-767. doi: 10.1016/S0140-6736(22)01429-5. Epub 2022 Aug 27.
3
Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction.既往心力衰竭住院对射血分数降低和保留患者心血管事件的影响。
Circ Heart Fail. 2014 Jul;7(4):590-5. doi: 10.1161/CIRCHEARTFAILURE.113.001281. Epub 2014 May 29.
4
Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).根据心力衰竭和射血分数保留患者的糖尿病状态的临床和超声心动图特征和心血管结局：来自 I-Preserve 试验（伊贝沙坦治疗射血分数保留心力衰竭）的报告。
Circulation. 2017 Feb 21;135(8):724-735. doi: 10.1161/CIRCULATIONAHA.116.024593. Epub 2017 Jan 4.
5
Burden of Recurrent Hospitalizations Following an Admission for Acute Heart Failure: Preserved Versus Reduced Ejection Fraction.急性心力衰竭入院后再入院负担：射血分数保留与降低情况对比
Rev Esp Cardiol (Engl Ed). 2017 Apr;70(4):239-246. doi: 10.1016/j.rec.2016.06.021. Epub 2016 Nov 3.
6
Current Prevalence, Incidence, and Outcomes of Heart Failure with Preserved Ejection Fraction.射血分数保留的心力衰竭的当前患病率、发病率和结局。
Heart Fail Clin. 2021 Jul;17(3):315-326. doi: 10.1016/j.hfc.2021.03.002.
7
The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).射血分数保留的心力衰竭患者的住院负担和住院后死亡率风险：I-PRESERVE 试验（伊贝沙坦治疗心力衰竭和保留射血分数）的结果。
JACC Heart Fail. 2015 Jun;3(6):429-441. doi: 10.1016/j.jchf.2014.12.017. Epub 2015 May 14.
8
Prognostic Value of Depressive Symptoms for Cardiovascular Events in Female Patients With Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction.抑郁症状对射血分数降低型心力衰竭和射血分数保留型心力衰竭女性患者心血管事件的预后价值。
J Am Heart Assoc. 2024 May 7;13(9):e032961. doi: 10.1161/JAHA.123.032961. Epub 2024 Apr 30.
9
Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER.达格列净的疗效与心率的关系：DAPA-HF 和 DELIVER 的患者水平汇总分析。
Circ Heart Fail. 2023 Dec;16(12):e010898. doi: 10.1161/CIRCHEARTFAILURE.123.010898. Epub 2023 Oct 27.
10
Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis.药物治疗对射血分数保留的心力衰竭结局的影响：系统评价和荟萃分析。
Heart. 2018 Mar;104(5):407-415. doi: 10.1136/heartjnl-2017-311652. Epub 2017 Aug 5.
本文引用的文献
1
Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management.射血分数保留的心力衰竭：诊断、机制与管理的最新概念
Heart. 2022 Aug 11;108(17):1342-1350. doi: 10.1136/heartjnl-2021-319605.
2
Cardiotoxicity of Anthracyclines.蒽环类药物的心脏毒性
Front Cardiovasc Med. 2020 Mar 18;7:26. doi: 10.3389/fcvm.2020.00026. eCollection 2020.
3
Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary.射血分数保留的心力衰竭研究重点：美国国立心肺血液研究所工作组总结。
Circulation. 2020 Mar 24;141(12):1001-1026. doi: 10.1161/CIRCULATIONAHA.119.041886. Epub 2020 Mar 23.
4
Trastuzumab-Induced Cardiomyopathy.曲妥珠单抗相关性心肌病。
Cardiol Clin. 2019 Nov;37(4):407-418. doi: 10.1016/j.ccl.2019.07.005. Epub 2019 Aug 27.
5
Adjuvant radiotherapy-induced cardiac changes among patients with early breast cancer: a three-year follow-up study.辅助放疗引起的早期乳腺癌患者心脏变化：一项为期三年的随访研究。
Acta Oncol. 2019 Sep;58(9):1250-1258. doi: 10.1080/0284186X.2019.1630751. Epub 2019 Jun 20.
6
Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes.心力衰竭伴射血分数保留、轻度降低和中度降低：5 年结局。
J Am Coll Cardiol. 2017 Nov 14;70(20):2476-2486. doi: 10.1016/j.jacc.2017.08.074. Epub 2017 Nov 12.
7
Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population.曲妥珠单抗所致心脏毒性：在真实世界心脏肿瘤学人群中测试临床风险评分
Curr Oncol. 2017 Jun;24(3):176-180. doi: 10.3747/co.24.3349. Epub 2017 Jun 27.
8
Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.芳香化酶抑制剂和他莫昔芬对绝经后乳腺癌女性的心脏毒性：随机对照试验的系统评价和荟萃分析
Ann Oncol. 2017 Mar 1;28(3):487-496. doi: 10.1093/annonc/mdw673.
9
Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.乳腺癌辅助曲妥珠单抗治疗后心力衰竭和心肌病的风险预测模型。
J Am Heart Assoc. 2014 Feb 28;3(1):e000472. doi: 10.1161/JAHA.113.000472.
10
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.健康绝经后妇女使用雌激素加孕激素的风险与益处：妇女健康倡议随机对照试验的主要结果
JAMA. 2002 Jul 17;288(3):321-33. doi: 10.1001/jama.288.3.321.
Zotero 插件